OBJECTIVETo investigate the expression and significance of transforming growth factor-β(1) (TGF-β(1)) and Ki-67 nuclear antigen in salivary gland mucoepidermoid carcinoma.

METHODSThe expression of TGF-β(1) and Ki-67 nuclear antigen in 20 cases of salivary gland pleomorphic adenoma and 45 cases of mucoepidermoid carcinoma were detected by the streptavidin-peroxidase immunohistochemical method.

RESULTSExpression of TGF-β(1) (39/45) and Ki-67 nuclear antigen (43/45) in mucoepidermoid carcinoma was significantly higher than in pleomorphic adenoma (P < 0.05). TGF-β(1) expression was significantly higher in moderately/poorly differentiated mucoepidermoid carcinoma (16/16) than that in well differentiated mucoepidermoid carcinoma (23/29) and pleomorphic adenoma (12/20) (P < 0.05), but not different between well differentiated mucoepidermoid carcinoma (6/23) and pleomorphic adenoma (8/12) (P > 0.05). The expression of Ki-67 was increased with the increment of TGF-β(1) expression in mucoepidermoid carcinoma (P < 0.05).

CONCLUSIONSThe high expression of TGF-β(1) may play an important role in cell differentiation and malignant proliferation of mucoepidermoid carcinoma.

Adenoma, Pleomorphic ; metabolism ; pathology ; Adolescent ; Adult ; Carcinoma, Mucoepidermoid ; metabolism ; pathology ; Cell Differentiation ; Female ; Humans ; Ki-67 Antigen ; metabolism ; Male ; Middle Aged ; Salivary Gland Neoplasms ; metabolism ; pathology ; Transforming Growth Factor beta1 ; metabolism ; Young Adult

Objective: To compare the short-term and long-term prognosis of irreversible electroporation(IRE) and conversional resection for locally advanced pancreatic cancer(LAPC). Methods: The clinical and pathological data of 98 LAPC patients who underwent IRE or conversional resection at the Department of Pancreatobiliary Surgery,Sun Yat-sen University Cancer Center from August 2015 to December 2020 were retrospectively collected and analyzed.The study comprised of 53 males and 45 females, with age(M(IQR)) of 57.5(13.5)years old(range:20 to 87 years old). Fifty-three patients received IRE treatment(IRE group) and 45 patients received surgical resection(resection group). The differences of clinical and pathological data between both groups were not significant(all P<0.05). The Mann-Whitney U test was used for quantitative data and the χ² test was used for categorical data.Survival was analyzed using Kaplan-Meier method and compared using Log-rank test. Results: The operation time and intraoperative blood loss were 5.0(2.4)hours and 50(100) ml in the IRE group,respectively,which were significantly less than those of resection group(7.0(3.3)hours and 400(200)ml,both P<0.05).The hospital stay and hospitalization cost were 9.0(3.0)days and 79 154 (83 738) yuan in the IRE group,respectively,which were also significantly less than those in the resection group(16.0(8.5)days and 109 557(37 795)yuan,both P<0.05).The complication rate of IRE group was significantly lower than that of the resection group(18.8% vs. 55.6%,χ²=14.270,P<0.01).The median overall survival(OS) time of IRE group was 28.9 months(95%CI:23.2 to 34.6 months),with the 1-,2-,and 3-year OS rates of 91.6%,61.7%,and 24.6%,respectively.The median survival of OS of resection group was 27.1 months(95%CI:20.9 to 33.3 months),with the 1-,2-,and 3-year OS rates of 81.8%,53.9%,and 30.3%,respectively.There was no significant difference in OS between the two groups(χ²=0.900,P=0.760).The median progression free survival(PFS) time of IRE group was 18.0 months(95%CI:14.7 to 21.3 months),with the 1-,2-,and 3-year PFS rates of 68.3%,29.7%,and 9.9%,respectively.The median survival of PFS of resection group was 11.1 months(95%CI:6.1 to 16.2 months),with the 1-,2-,and 3-year PFS rates of 45.2%,21.9%,and 14.6%,respectively.There was no significant difference in PFS between the two groups(χ²=1.850,P=0.170). Conclusion: IRE can achieve similar survival for LAPC and may has less complications compared to those with conversion resection.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Electroporation/methods* ; Female ; Humans ; Male ; Middle Aged ; Neoplasms, Second Primary ; Pancreas/pathology* ; Pancreatic Neoplasms/pathology* ; Prognosis ; Retrospective Studies ; Treatment Outcome ; Young Adult

INTRODUCTIONMost hepatocellular carcinomas (HCC) develop in a background of underlying liver disease including chronic hepatitis B. However, the effect of antiviral therapy on the long-term outcome of patients with hepatitis B virus (HBV)-related HCC treated with chemoembolization is unclear. This study aimed to evaluate the survival benefits of anti-HBV therapy after chemoembolization for patients with HBV-related HCC.

METHODSA total of 224 HCC patients who successfully underwent chemoembolization were identified, and their survival and other relevant clinical data were reviewed. Kaplan-Meier and Cox regression analyses were performed to validate possible effects of antiviral treatment on overall survival (OS).

RESULTSThe median survival time (MST) was 15.9 (95% confidence interval [CI], 9.5-27.7) months in the antiviral group and 9.6 (95% CI, 7.8-13.7) months in the non-antiviral group (log-rank test, P = 0.044). Cox multivariate analysis revealed that antiviral treatment was a prognostic factor for OS (P = 0.008). Additionally, a further analysis was based on the stratification of the TNM tumor stages. In the subgroup of early stages, MST was significantly longer in the antiviral-treatment group than in the non-antiviral group (61.8 months [95% CI, 34.8 months to beyond the follow-up period] versus 26.2 [95% CI, 14.5-37.7] months, P = 0.012). Multivariate analysis identified antiviral treatment as a prognostic factor for OS in the early-stage subgroup (P = 0.006). However, in the subgroup of advanced stages, MST of the antiviral-treated group was comparable to that of the non-antiviral group (8.4 [95% CI, 5.2-13.5] months versus 7.4 [95% CI, 5.9-9.3] months, P = 0.219). Multivariate analysis did not indicate that antiviral treatment was a significant prognostic factor in this subgroup.

CONCLUSIONAntiviral treatment is associated with prolonged OS time after chemoembolization for HCC, especially in patients with early-stage tumors.

Antiviral Agents ; Carcinoma, Hepatocellular ; Chemoembolization, Therapeutic ; Drug Therapy, Combination ; Hepatitis B virus ; Hepatitis B, Chronic ; Humans ; Liver Neoplasms ; Mortality ; Neoplasm Staging ; Prognosis ; Retrospective Studies